Table 1.
Clinical characteristics of the patients.
| All | Early Progression | p | ||
|---|---|---|---|---|
| (N = 28) | No (N = 21) | Yes (N = 7) | ||
| Age (years) (IQR) | 50.0 (42.5;56.0) | 50.0 (47.0;56.0) | 46.0 (35.0;51.5) | 0.184 |
| FIGO staging 2018, n (%) | 0.298 | |||
| - IB | 4 (14.3%) | 3 (14.3%) | 1 (14.3%) | |
| - IIB-IIIC1 | 14 (50.0%) | 12 (57.1%) | 2 (28.6%) | |
| - IIIC2-IVA | 7 (25.0%) | 5 (23.8%) | 2 (28.6%) | |
| - IVB | 3 (10.7%) | 1 (4.8%) | 2 (28.6%) | |
| Pathology, n (%) | 0.017 | |||
| - Adenocarcinoma | 4 (14.3%) | 1 (4.8%) | 3 (42.9%) | |
| - Adenosquamous cell carcinoma | 1 (3.6%) | 0 (0.0%) | 1 (14.3%) | |
| - Unclassified carcinoma | 1 (3.6%) | 1 (4.8%) | 0 (0.0%) | |
| - Squamous cell carcinoma | 22 (78.6%) | 19 (90.5%) | 3 (42.9%) | |
| RT field, n (%) | 0.815 | |||
| Pelvis | 19 (67.9%) | 15 (71.4%) | 4 (57.1%) | |
| Pelvis with para-aortic region | 9 (32.1%) | 6 (28.6%) | 3 (42.9%) | |
| Total dose (EQD2) (IQR) | 76.2 (72.2;84.2) | 75.5 (72.2;84.2) | 84.2 (74.2;84.2) | 0.357 |
| Intracavitary brachytherapy, n (%) | 0.483 | |||
| - No treatment | 2 (7.1%) | 1 (4.8%) Refusal | 1 (14.3%) EBRT | |
| - 24 Gy in four fractions | 10 (35.7%) | 9 (42.9%) | 1 (14.3%) | |
| - 24 Gy in six fractions | 5 (17.9%) | 4 (19.0%) | 1 (14.3%) | |
| - 25 Gy in five fractions | 1 (3.6%) | 1 (4.8%) | 0 (0.0%) | |
| - 30 Gy in six fractions | 10 (35.7%) | 6 (28.6%) | 4 (57.1%) | |
| Dexamethasone during RT, n (%) | 1.000 | |||
| No | 21 (75.0%) | 16 (76.2%) | 5 (71.4%) | |
| Yes | 7 (25.0%) | 5 (23.8%) | 2 (28.6%) | |
| Dexamethasone after RT, n (%) | 0.061 | |||
| No | 24 (85.7%) | 20 (95.2%) | 4 (57.1%) | |
| Yes | 4 (14.3%) | 1 (4.8%) | 3 (42.9%) | |
| Death, n (%) | 0.014 | |||
| No | 25 (89.3%) | 21 (100.0%) | 4 (57.1%) | |
| Yes | 3 (10.7%) | 0 (0.0%) | 3 (42.9%) | |
RT, radiotherapy; EQD2, equivalent dose in 2 Gy fractions; FIGO, International Federation of Gynecology and Obstetrics; IQR, interquartile range.